Antibody Production
Engaging two targets at once for synergistic biology — an innovative option for next-generation immunotherapy.
SanjingBio focuses on custom expression and development of bispecific antibodies. Built by genetic engineering, a bispecific recognises two different antigens at once, forming a specific bridge between target cells and effector cells or functional molecules to direct a precise immune response.
Their distinctive mechanism and clear clinical potential — especially in cancer immunotherapy — have made bispecifics a major direction in antibody engineering.
On a mature mammalian platform backed by extensive recombinant antibody experience, we provide one-stop bispecific expression from gene sequence to purified protein. Supported formats include BiTE, Diabody, CrossMab and DVD-Ig, with multiple design strategies and rapid process development.
Enquire now →
Several proven bispecific construction platforms address the poor homogeneity of heterodimers.
Homogeneity ≥90% with both antigen-binding activities retained, safeguarding targeting and therapeutic effect.
GMP-aligned practice and a dedicated quality system keep the product compliant.
Molecular formats can be customised and production run at several scales, bridging development and commercialisation.
Six stages, supporting multiple design strategies and rapid process development; outputs and acceptance criteria are in the specifications below.
Bispecific antibody genes are synthesized, codon-optimized and sequence-verified
Mammalian expression vectors are built and sequence-verified for the selected bispecific design
Transient mammalian expression that tackles heterodimer homogeneity
Affinity chromatography to ≥90% homogeneity
Structural integrity and purity confirmed by R/NR SDS-PAGE
Purified bispecific sample and sequencing report delivered
Gene synthesis through purified delivery totals roughly 5–7 weeks; BiTE, Diabody, CrossMab, DVD-Ig and other mainstream formats are supported.
Multiple proven bispecific platforms deliver ≥90% homogeneity while both antigen-binding activities stay intact. GMP-aligned practice and a dedicated QC system support custom molecule design and multi-scale production, bridging R&D and commercialisation.
Deliverables, acceptance criteria and timelines by experimental stage. The staging differs from the process above: the process shows how a project runs, while this table is the acceptance basis written into the contract.
| Stage | Scope | Deliverables | Standards | Timeline |
|---|---|---|---|---|
| Gene synthesis & cloning | Sequence synthesis and vector construction | Sequencing report | Sequence verified | 2–3 weeks |
| Large-scale recombinant antibody expression | Transient expression and purification | Purified antibody sample | Purity ≥95% | 3–4 weeks |
To the customer's specification, the mammalian platform handled gene synthesis with codon optimisation, vector construction, transient expression and affinity purification of the bispecific antibody, followed by SDS-PAGE under reducing (R) and non-reducing (NR) conditions to characterise structural integrity and purity.
Under reducing conditions clear bands appear at ~64 kDa (heavy chain) and ~36 kDa (light chain); non-reducing conditions show the intact antibody at ~200 kDa. Bands are single and impurity-free, purity >95%, and the structure and molecular weights match theory exactly.
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
